eng Oriental Scientific Publishing Company Biomedical and Pharmacology Journal 0974-6242 2019-03-25 12 1 227 232 10.13005/bpj/1631 26571 article I. Dewa Made Widi Hersana 1 Ugroseno Yudho Bintoro 1 Ami Ashariati 1 Made Putra Sedana 1 Hematology and Medical Oncology Division, Department of Internal Medicine, Universitas Airlangga-Dr Soetomo Teaching Hospital, Surabaya, Indonesia. The aim of the study is to to determine correlation Hasford score and early molecular response in chronic phase BCR-ABL-Positive CML patients treated with imatinib. This is an longitudinal observational study in newly diagnosed patients of CML chronic phase BCR-ABL-Positive treated imatinib from Januari 2017 to September 2017. Patients were stratified according to Hasford score at diagnosis. Q-PCR(Quantitative RT-PCR) were used to monitor BCR-ABL transcription levels after 3 months of imatinib treatment.  Correlation between Hasford score with early molecular response were analyzed using Koefisien Kontingensi’s correlation test. Results: Thirty five patients were enrolled in this study consist of 13 male and 22 female. After 3 months of imatinib treatment, EMR were 5 patients (83.3%), 11 patients (61.1%) and 2 patients (18.2%) in low, intermediate, and high risk group patients, respectively. Koefisien kontigensi test showed that there was significant correlation between Hasford score and EMR (p=0.018; r=0.431). The Hasford score correlated to early molecular response in chronic phase BCR-ABL-positive CML patients received imatinib. https://biomedpharmajournal.org/vol12no1/correlation-between-hasford-score-with-early-molecular-response-in-patients-with-chronic-myeloid-leukemia-in-chronic-phase-treated-with-imatinib/ Chronic Phase BCR-ABL-Positive CML  Early Molecular Response  Hasford Score  Imatinib